Central cardiovascular effects of intracerebroventricular propranolol.
D000311:Adrenal Glands / Q000502:physiology; D000313:Adrenal Medulla / Q000187:drug effects; D000315:Adrenalectomy; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000818:Animals; D001285:Atropine / Q000494:pharmacology; D002319:Cardiovascular System / Q000187:drug effects*; D002395:Catecholamines / Q000097:blood / Q000378:metabolism; D002552:Cerebral Ventricles; D004285:Dogs; D006892:Hydroxydopamines / Q000494:pharmacology; D007267:Injections; D010643:Phenoxybenzamine / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology*; D011941:Receptors, Adrenergic / Q000187:drug effects; D011950:Receptors, Cholinergic / Q000187:drug effects; D013050:Spectrometry, Fluorescence; D013233:Stellate Ganglion / Q000502:physiology; D013997:Time Factors; D014628:Vagotomy; D014630:Vagus Nerve / Q000502:physiology; D015016:Yohimbine / Q000494:pharmacology
D000317:Adrenergic alpha-Antagonists; D002395:Catecholamines; D006892:Hydroxydopamines; D011941:Receptors, Adrenergic; D011950:Receptors, Cholinergic; D010643:Phenoxybenzamine; D015016:Yohimbine; D001285:Atropine; D011433:Propranolol